ArticlePloS one2025
Integrated multi-omics analysis reveals necroptosis-related biomarker BIRC3 for early diagnosis and therapeutic targeting in preeclampsia.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extracellular Vesicle-Associated Non-Coding RNAs in Preeclampsia: Mechanistic Insights, Biomarker Discovery, and Emerging Nanomedicine Concepts.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPreeclampsia (PE) is a life-threatening pregnancy disorder lacking reliable early biomarkers. While apoptosis is implicated in PE pathogenesis, the role of regulated necrotic cell death (necroptosis) remains poorly understood. This study aimed to identify necroptosis-related biomarkers, and further provide the potential natural compounds for PE with virtual screening.
methodsPublic datasets (GSE66273 for training set; GSE44711 for validation set; GSE173193 for single-cell RNA-seq) were analyzed. Differentially expressed genes (DEGs) were screened using limma (|log2FC| > 1, P < 0.05). Necroptosis-related genes overlapped with DEGs to identify key candidates. Subsequent analyses included machine learning, protein-protein interaction (PPI) network construction, and immune infiltration profiling. Single-cell RNA sequencing data (GSE173193) was utilized to localize BIRC3 expression at the cellular level. Transcription factors, microRNAs, and RNA-binding proteins associated with BIRC3 are also identified. Finally, Molecular docking predicted therapeutic drugs targeting hub genes.
resultsThe analysis of the GSE66273 dataset identified 367 DEGs. Intersection with necroptosis-related genes revealed 3 necroptosis-related DEGs (NRDEGs), from which BIRC3 was prioritized as hub gene through PPI networks and machine learning (random forest). BIRC3 demonstrated significant diagnostic potential in the discovery cohort (AUC = 0.933) and maintained strong performance in the independent validation cohort (AUC = 0.844). Single-cell analysis revealed BIRC3 was predominantly expressed in immune lineages, particularly NK/T cells, with a significantly higher proportion of BIRC3-positive cells in PE placentas (p < 0.05). Immune microenvironment further analysis demonstrated significant dysregulation in PE. Finally, based on the BIRC3 structure, Withanolide D (-11.0 kcal/mol), Baicalin (-9.0 kcal/mol) and Mangostin (-8.3 kcal/mol) were screened.
conclusionThis comprehensive analysis implicates necroptosis in PE pathogenesis. BIRC3 is proposed as a novel diagnostic biomarker and therapeutic target, with multi-omics validation underscoring its role in immune dysregulation and placental dysfunction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.